BSIM Therapeutics

We’re pleased to announce the selection of our first drug candidate, BSIM 3A05D, a compound designed to address #ATTR-CM, a progressive and potentially fatal disease characterized by deposition of TTR amyloid in the heart. Full PR: bsimtx.com/news/28 #amyloidosis

More than 300 M people worldwide live with a rare disease. Today BSIM joins #RareDiseaseDay observance and reaffirms its commitment towards improving the quality of life of patients with #hATTR, a group of rare and severe conditions.

BSIM has been awarded two IP vouchers from the “@IdeasPowered for business #SMEFund”, a grant scheme designed by the @EU_IPO to help EU #SMEs protect their IP rights. We acknowledge this financial support and will use it to uphold our strong commitment to #IPprotection.

At the close of another year, BSIM Therapeutics wishes you a joyous Holiday Season and a New Year filled with peace and happiness.

Preclinical data obtained with the small molecule BSIM-3A05D show the compound effectively stabilizes transthyretin (TTR) and prevents #amyloid formation by different TTR variants with unprecedented efficacy. #cardiomyopathy #amyloidosis #ATTR-CM

BSIM Therapeutics has recently announced the selection of its first drug candidate – small molecule BSIM-3A05D – designed to prevent or treat hereditary and wild type transthyretin #amyloidosis with #cardiomyopathy presentation (#ATTR-CM).

Segundo o SIC Notícias,empresa de biotecnologia anunciou a seleção de um medicamento para tratar a Amiloidose Cardíaca.. Leia: sicnoticias.pt/saude-e-bem-es… .

Empresa de Coimbra desenvolve medicamento experimental para doença rara que afeta o coração sicnoticias.pt/saude-e-bem-es…

Empresa de Coimbra desenvolve medicamento experimental para doença rara no coração dlvr.it/SCl7rm

A BSIM Therapeutics anuncia a seleção de Composto Candidato para o tratamento da Cardiomiopatia Amilóide associada a Transtirretina (ATTR-CM), uma potencial nova arma terapêutica contra um inimigo silencioso. Mais informações em bsimtx.com

Today, BSIM is sharing drug R&D work and experience with other companies and research labs at INOVAÇÃO@UC, an event to promote networking and collaboration among researchers at the University of Coimbra, tech companies, and other R&D institutions. More at inova.uc.pt

For the second time around, BSIM has been awarded a US patent (# 11,117,877) for a novel technology for the treatment of #ATTR. This is a step forward in the consolidation of a strong IP portfolio and in our efforts to answer to unmet medical needs of ATTR patients. #amyloidosis

#Amyloid diseases are wide ranging, progressive and most times fatal. Early and accurate diagnosis is central to patient care. BSIM supports @AmyloidosisA effort in raising awareness of amyloid diseases in this first #WorldAmyloidosisDay. Check the program worldamyloidosisday.org

(2.) In this #WorldHeartDay BSIM joins the World in raising awareness for cardiac diseases and reaffirms its commitment to work for therapeutic solutions in the treatment of TTR-related amyloidosis with cardiac involvement (#ATTR-CM). #CardiacAmyloidosis #ATTRCM

(1.) Did you know that cardiac involvement in TTR-related amyloidosis (#ATTR-CM) is associated with heart failure with preserved ejection fraction and has an incidence of approx. 3 cases per 10.000 in the European Union? #WorldHeartDay #CardiacAmyloidosis link.springer.com/article/10.100…

@DDNewsOnline Thank you. Follow us on Twitter (@BSIMtx) and stay up to date with the news :)

BSIM keeps on striving to develop innovative therapeutic solutions endowed with the pharmacodynamics and pharmacokinetics properties to address the unmet medical needs in ATTR (3/3). #ATTR #hATTR #Amyloidosis #amyloidosisawareness #BSIMTherapeutics #BSIMtx

Moreover, the increasing clinical importance of cardiac manifestations of #ATTR and the efforts being made to address them through diagnostic tools and therapeutic approaches have been extensively pointed out by several speakers (2/3). #CardiacAmyloidosis #ATTRCM

Earlier this month, BSIM attended the “3rd European ATTR Amyloidosis meeting for Patients and Doctors”. The increasing incidence and impact of CNS impairment in #ATTR have received new attention, emphasizing the urgent need of more tailored and organ-targeted therapeutics (1/3).

At BSIM Therapeutics we strive to discover and develop innovative therapeutic solutions with one goal in mind: to improve the quality of life of patients suffering from transthyretin amyloidosis with polyneuropathy and cardiomyopathy (#ATTR #hATTR #ATTRCM #CardiacAmyloidosis).